CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The American Society for Radiation Oncology (ASTRO) annual general meeting was held from September 27 ‒ October 1, 2025. Below are some of the research presentations that CCTG played a role in.
MAC25 (NRG-BR004): A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer trial has closed.
CRC6 (CALGB C80702): A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer trial has permanently closed.
IND.238 sub-study A is a phase II study of Durvalumab in patients who discontinued prior checkpoint therapy due to immune related toxicity has closed to accrual. Treatment and follow up for sub-study A patients will continue as per protocol.
Call for Applications: American Association for Cancer Research Scientist↔Survivor Program®
CCTG is upgrading the login platform to Auth0 by Okta for a more secure and seamless login experience. The new login screen is designed to be simple and user-friendly, allowing users to log in using existing credentials. This change ensures faster, more reliable access to your account with fewer sign ins, while keeping your data safe.
NEC3 (Alliance A021202) was a randomized phase II trial of pazopanib versus placebo in patients with advanced extrapancreatic neuroendocrine tumors
